Table 3 Response to TNF-α treatment. Percent changes of biomarkers from baseline to weeks 22 and 46 in patients with and without a BASDAI response, respectively

PRO-C1

Median (IQR)

− 3.1

(− 33.2, 13.9)

14.2

(5.1, 36.1)

0.020

6.2

(− 15.4, 24.1)

12.8

(1.5, 36.1)

0.432

PRO-C3

Median (IQR)

− 6.0

(− 27.6, 8.4)

4.0

(− 11.0, 28.6)

0.186

− 1.4

(− 17.0, 25.5)

6.5

(− 11.0, 28.6)

0.552

PRO-C4

Median (IQR)

− 12.7

(− 28.1, 28.9)

− 8.1

(− 25.3, 17.8)

0.832

− 11.9

(− 29.2, 10.1)

− 8.4

(− 25.7, 22.4)

0.710

PRO-C6

Median (IQR)

− 2.5

(− 13.8, 8.7)

− 0.4

(− 12.1, 19.1)

0.349

− 0.4

(− 16.0, 19.9)

0.2

(− 12.4, 14.2)

0.868

C3M

Median (IQR)

15.3

(− 7.1, 21.9)

4.5

(− 9.2, 15.0)

0.331

5.7

(− 8.9, 20.4)

6.0

(− 9.5, 16.4)

0.739

C4M

Median (IQR)

2.7

(− 14.2, 15.1)

− 6.8

(− 13.7, 5.5)

0.517

− 11.3

(− 14.8, 2.4)

− 6.4

(− 12.2, 6.7)

0.421

C6M

Median (IQR)

− 3.7

(− 39.0, 32.1)

− 32.0

(− 63.7, 4.5)

0.049

− 9.9

(− 56.3, 48.2)

− 30.6

(− 53.9, 17.1)

0.485

C7M

Median (IQR)

− 29.1

(− 42.5, 34.8)

− 28.9

(− 54.5, 8.4)

0.737

− 22.2

(− 56.1, 39.6)

− 30.0

(− 51.5, 0.0)

0.642

C10C

Median (IQR)

9.2

(− 9.2, 21.0)

2.4

(− 5.5, 15.0)

0.873

13.4

(− 4.3, 22.4)

2.1

(− 8.7, 14.5)

0.403

CRPM

Median (IQR)

− 1.8

(− 11.0, 6.8)

− 3.6

(− 14.7, 16.3)

0.854

1.5

(− 8.2, 10.7)

− 4.2

(− 13.1, 10.6)

0.490

EL-NE

Median (IQR)

0.0

(0.0, 11.6)

0.0

(− 31.9, 0.9)

0.222

0.2

(0.0, 23.1)

0.0

(− 32.6, 8.0)

0.212

VICM

Median (IQR)

− 17.3

(− 63.6, 49.1)

− 36.3

(− 66.0, 9.4)

0.559

− 16.1

(− 70.3, 27.8)

− 37.9

(− 64.9, 42.3)

0.926

CRP

Median (IQR)

− 56.7

(− 82.66–26.78)

− 83.64

(− 94.10–58.75)

0.086

183.3

(− 33.81–458.11)

− 9.5

(60.34–120.71)

0.456